/ /

  • linkedin
  • Increase Font
  • Sharebar

    New drug aims to treat intraoperative miosis, reduce pain

    Intracameral phenylephrine, ketorolac injection yields benefits during cataract surgery, IOL replacement



    A recently approved intracameral phenylephrine and ketorolac 1%/0.3% product is expected to produce better surgical outcomes following cataract surgery or IOL replacement by preventing miosis and reducing intraoperative pain.



    New York—Intracameral phenylephrine and ketorolac injection 1%/0.3% (Omidria, Omeros Corp.)—approved by the FDA for its combined properties of maintaining pupil dilation and reducing pain—is expected to provide multiple advantages to both surgeons and patients during cataract surgery or IOL replacement.


    RELATED SIDEBAR: What drug therapy means for preoperative regimen


    “The goal is to maintain intraoperative mydriasis, to reduce inflammation at the time of surgery, and to reduce the pain associated with surgery,” said Eric D. Donnenfeld, MD, who helped in the clinical trials for the product. Dr. Donnenfeld is a founding partner of Ophthalmic Consultants of Long Island and Connecticut and clinical professor ophthalmology, New York University Medical Center, New York.

    Phenylephrine, acting as a mydriatic agent, contracts the radial muscle of the iris, while ketorolac inhibits both cyclooxygenase enzymes, providing a reduction in pain through a decrease in the production of prostaglandins.

    “This product is in the perfect place at the perfect time, in that surgeons are looking for both better surgical outcomes and ways to make the procedure more comfortable for patients,” Dr. Donnenfeld said. “We know that a well-dilated pupil improves operative results, reduces complications, and reduces total surgical and phacoemulsification time, so patients end up having more rapid return of visual acuity.”

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results